血管免疫母细胞性T细胞淋巴瘤患者EB病毒感染情况及其临床意义

Abstract

目的 探讨血管免疫母细胞性T细胞淋巴瘤患者的EB病毒感染情况及其临床病理学意义.方法 回顾性分析2008年1月至2011年12月经常规外检及会诊确诊的血管免疫母细胞性T细胞淋巴瘤62例,进行常规形态学和免疫学表型分析,采用原位杂交方法检测EB病毒编码小RNA(EBV-EBER)的表达情况,并随访患者.结果 62例血管免疫母细胞性T细胞淋巴瘤患者中,EBV-EBER阳性者26例(42％).EBV-EBER表达与患者年龄大于60岁以及治疗反应密切相关(P=0.025、0.049),而与患者的总体生存时间、临床B症状及Ann Arbor分期无关(均P＞0.05).结论 血管免疫母细胞性T细胞淋巴瘤患者EB病毒感染不影响总体生存时间,但影响患者对治疗的反应.

Objective To investigate the EB virus (EBV) infection and its clinical significance in angioimmunoblastic T-cell lymphoma(AITCL).Methods 62 patients diagnosed as AITCL between 2008 Jan and 2011 Dec were retrospective analyzed.All cases were re-confirmed and classified with the histology and immunology according to 2008 WHO Classification.In situ hybridization of EBV encoded RNA (EBV-EBER) was performed.Clinical characteristics and follow-up data of patients were collected.Results 42 ％ (26/62) AITCL cases were EBER-positive.EBV infection was found to be significant correlation with age over 60 years and poor response to therapy (P =0.025,P =0.049,respectively).However,EBV infection had no relationship with the overall survival,the presence of B symptom and the Ann Arbor stage.Conclusion In AITCL,EBV infection seems not to be associated with the overall survival,B symptom and Ann Arbor stage,but it may have impacts on theraputic response.